AzTrials
AzTrials

Labral Tear, GlenoidNCT03985839

Safety and Performance of MICRORAPTOR™ Suture Anchors in Shoulder and Hip

An observational study of Labral Tear, Glenoid and Acetabular Labrum Tear, run by Smith & Nephew, Inc. at 12 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a prospective, multi-center, PMCF study to evaluate the safety and performance of the MICRORAPTOR REGENESORB suture anchors, MICRORAPTOR Knotless REGENESORB suture anchors, and MICRORAPTOR Knotless PEEK suture anchors implanted in 315 subjects needing reattachment of soft tissue to bone. Read more about this study

Who is it for?
Ages 12 years and older
What is being tested?
MICRORAPTOR™ REGENESORB™ Suture Anchor, MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor
Type of treatment
Medical device
How many people
298 participants
Where
12 sitesUnited States
Study dates
1 Aug 2019to 8 Aug 2024
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Subject requires reattachment of soft tissue to bone for the following indications: * Shoulder - Capsular stabilization for Bankart repair, Anterior shoulder instability, SLAP lesion repairs, Capsular shift or capsulolabral reconstructions, Biceps tenodesis, Rotator Cuff Repairs (knotless anchors only) * Hip - Acetabular labrum repair/reconstruction

Who may be able to join

  • Subject requires reattachment of soft tissue to bone for one of the following indications:
  • Shoulder - Capsular stabilization for Bankart repair, anterior shoulder instability, superior labrum from anterior to posterior (SLAP) lesion repairs, capsular shift or capsulolabral reconstructions; biceps tenodesis (knotless anchors only)
  • Hip - Acetabular labrum repair/reconstruction
  • Subject if ≥ 18 years of age or legally authorized representative if subject is <18 years of age has consented to participate in the study by signing the IRB approved informed consent form. If <18 years of age, subject has assented to participate in the study by signing the IRB approved assent form.
  • Subject is ≥12 years of age at time of surgery.
  • Willing and able to make all required study visits.
  • Able to follow instructions.

Who cannot join

  • Known hypersensitivity to the implant material. Where material sensitivity is suspected, appropriate tests should be made and sensitivity ruled out prior to implantation.
  • Pathological conditions of bone, such as cystic changes or severe osteopenia, which would compromise secure anchor fixation.
  • Pathological conditions in the soft tissues to be attached that would impair secure fixation by suture.
  • Comminuted bone surface, which would compromise secure anchor fixation.
  • Physical conditions which would eliminate, or tend to eliminate, adequate anchor support or retard healing.
  • The presence of infection.
Show all 15Show fewer
  • Conditions which would limit the subject's ability or willingness to restrict activities or follow directions during the healing period.
  • Currently using tobacco products (cigarette, smokeless tobacco, e-cigarettes, vaping etc.).
  • Concurrent bilateral surgery.
  • Prior MICRORAPTOR™ REGENESORB™, MICRORAPTOR™ Knotless REGENESORB™ or MICRORAPTOR™ Knotless PEEK implantation.
  • Participation in the treatment period of another clinical trial within thirty (30) days of Visit 1, or during the study.
  • Women who are pregnant or nursing.
  • History of poor compliance with medical treatment.
  • Prior ipsilateral surgeries performed on the joint space.
  • Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.

Trial locations and contacts

12 sites in 1 country.

12 sites in 1 country

United States12 sites
  • Luminis Health Research Institute

    Annapolis, Maryland, 21401

  • Memorial Medical Center

    Ashland, Wisconsin, 54806

  • University of Colorado

    Aurora, Colorado, 80045

  • Emory University - Brookhaven

    Brookhaven, Georgia, 30329

  • Colorado Springs Orthopaedic Group

    Colorado Springs, Colorado, 80920

  • Palmetto/Prisma Health - University of South Carolina Orthopaedics

    Columbia, South Carolina, 29203

  • Ohio State University Wexner Medical Center

    Columbus, Ohio, 43202

  • Steadman Hawkins Clinic of the Carolinas

    Greenville, South Carolina, 29615

  • Holy Cross Orthopedic Institute

    Oakland Park, Florida, 33334

  • Oklahoma Sports and Science Orthopedics / The Physician's Group

    Oklahoma City, Oklahoma, 73114

  • Atlantic Orthopaedic Specialists

    Virginia Beach, Virginia, 23452

  • Center for Advanced Orthopaedics / Nova Orthopedic & Spine Care

    Woodbridge, Virginia, 22191

Other trials in United States

About this study

Official title: Prospective Multi-Center Post-Market Clinical Follow-up Study to Evaluate Safety and Performance of the MICRORAPTOR REGENESORB, Knotless REGENESORB and Knotless PEEK Suture Anchors (and MINITAPE Sutures) in Shoulder and Hip Arthroscopic Instability Repair

This is a prospective, multi-center, PMCF study to evaluate the safety and performance of the MICRORAPTOR REGENESORB suture anchors, MICRORAPTOR Knotless REGENESORB suture anchors, and MICRORAPTOR Knotless PEEK suture anchors implanted in 315 subjects needing reattachment of soft tissue to bone.

Read the detailed description

The purpose of this trial is to assess, by product, safety and performance post-market of the Microraptor Regenesorb, Microraptor Knotless Regenesorb, and Microraptor Knotless PEEK Suture Anchors.

Approximately 18 sites (approximately 3 sites for study shoulder group and 3 sites for study hip group, per product) in the United States will participate in the study. This is an open-label study with consecutive enrollment. The study will continue for 24 months from the date that the last subject received the study treatment to the date that the last subject completes the study as planned. The study duration is planned for 36 months.

Being tested
MICRORAPTOR™ REGENESORB™ Suture Anchor, MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor, MICRORAPTOR™ Knotless PEEK Suture Anchor
Keywords
Microraptor, suture anchor, knotless, Smith and Nephew
Medical subject headings
Rotator Cuff Injuries, Bankart Lesions

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MICRORAPTOR™ REGENESORB™ Suture AnchorDevice

    Smith \& Nephew MICRORAPTOR™ REGENESORB™ Suture Anchor is a fixation device intended to provide secure attachment of soft tissue to bone.

  • MICRORAPTOR™ Knotless REGENESORB™ Suture AnchorDevice

    MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor is fixation device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (REGENESORB™), and a non-absorbable PEEK (Polyether ether ketone) distal anchor tip.

  • MICRORAPTOR™ Knotless PEEK Suture AnchorDevice

    The MICRORAPTOR™ Knotless PEEK Suture Anchor is a class IIb device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (PEEK), and a non-absorbable PEEK distal anchor tip.

Study groups in NCT03985839
Study groupRoleWhat they receive
MICRORAPTOR™ REGENESORB™ Suture AnchorMICRORAPTOR™ REGENESORB™ Suture Anchor
Receives: Device: MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless REGENESORB™ Suture AnchorMICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Receives: Device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture AnchorMICRORAPTOR™ Knotless PEEK Suture Anchor
Receives: Device: MICRORAPTOR™ Knotless PEEK Suture Anchor

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Repair Failure Rate at 6 Months

    Repair failure at 6 months was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 6-month follow-up.

    Measured: 6 months

Secondary outcomes (11)
  1. Repair Failure Rate at 12 Months

    Repair failure at 12 months was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 12-month follow-up.

    Measured: 12 months

  2. Visual Analogue Scale (VAS) Pain Change From Baseline

    Pain was assessed using a Visual Analogue Scale (VAS) where participants indicated their pain level by marking a point that represented their perceived pain intensity. Scores ranged from 0 to 100, with 0 representing no pain and 100 representing the worst imaginable pain (i.e., a worse outcome). A decrease in VAS Pain score indicated a reduction in pain (i.e., a better outcome) and an increase indicated worsening in pain (i.e., a worse outcome). The mean change in pain score was recorded on the VAS from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.

    Measured: Baseline to 6 months, 12 months, and 24 months

  3. Repair Failure Rate at 24 Months (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY)

    Repair failure at 24 months was collected only for participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor. Repair failure was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 24-month follow-up.

    Measured: 24 months

  4. Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition

    Hip Magnetic Resonance Imagining (MRI) was performed on participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor to determine anchor absorption/replacement by bone at baseline, 6 months, and 24 months based on acetabular labral condition classification. The number of participants acetabular labral condition was classified as one of the following:

    • Normal Intact Labrum
    • Labral Tear / Degeneration

    Measured: Baseline, 6 months, and 24 months

  5. Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion

    Hip Magnetic Resonance Imagining (MRI) was performed on participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor to determine anchor absorption/replacement by bone at baseline, 6 months, and 24 months based on joint effusion classification. The number of participants joint effusion was classified as one of the following:

    • None
    • Mild
    • Moderate
    • Severe

    Measured: Baseline, 6 months, and 24 months

  6. Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema

    Hip Magnetic Resonance Imagining (MRI) was performed on participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor to determine anchor absorption/replacement by bone at baseline, 6 months, and 24 months based on the presence of bone marrow edema. The number of participants with bone marrow edema were categorized as 'Absent' or 'Present'.

    Measured: Baseline, 6 months, and 24 months

  7. Rowe Shoulder Score Change From Baseline (Shoulder Participants ONLY)

    The Rowe shoulder score for shoulder instability evaluated using a 3-item instrument completed by the investigator or qualified, delegated study staff. Its questions addressed the categories of shoulder stability (0 to 50 points), motion (0 to 20 points), and function (0 to 30 points). Scores ranged from 0 to 100 with a score of 90-100 points indicating an excellent evaluation, 75-89 points indicating a good evaluation, 51-74 points indicating a fair evaluation, and =< 50 points indicating a poor evaluation.

    An increase in Rowe score indicated reduced shoulder instability (i.e., a better outcome) and a decrease indicated worsening instability (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.

    Measured: Baseline to 6 months, 12 months, and 24 months

  8. Western Ontario Shoulder Instability Index (WOSI) Score Change From Baseline (Shoulder Participants ONLY)

    Western Ontario Shoulder Instability Index (WOSI) was a participant completed instrument. Its categories included "physical symptoms", "sports, recreation, work", "pain", "lifestyle", and "emotion", with questions within each category scored from 0 to 100 using a visual analog scale. Scores were combined to produce an overall score that ranged from 0 to 2100 with a score of 0 indicating better shoulder function and 2100 indicating worse shoulder function.

    A decrease in WOSI score indicated improving shoulder function (i.e., a better outcome) and an increase indicated worsening shoulder function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.

    Measured: Baseline to 6 months, 12 months, and 24 months

  9. Constant-Murley Shoulder Scale Change From Baseline (Should Participants ONLY)

    Constant-Murley Shoulder (CMS) scale assesses four aspects related to shoulder pathology: pain, activities of daily living (ADL), range of motion (ROM), and strength. The total score ranged from 0 to 100, with a higher score indicating better shoulder function.

    An increase in CMS score indicated improving shoulder function (i.e., a better outcome) and a decrease indicated worsening function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.

    Measured: Baseline to 6 months, 12 months, and 24 months

  10. Hip Outcome Score Activities of Daily Living (HOS-ADL) Score Change in Baseline (Hip Participants ONLY)

    The Hip Outcome Score Activities of Daily Living (HOS-ADL) subscale consisted of 17 items that addressed specific activities related to hip function. Scores ranged from 0 to 100 with 0 representing the least function and 100 representing the most function.

    An increase in HOS-ADL score indicated improved hip function (i.e., a better outcome) and a decrease indicated worsening function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.

    Measured: Baseline to 6 months, 12 months, and 24 months

  11. Modified Harris Hip Score (mHHS) Change From Baseline (Hip Participants ONLY)

    Modified Harris Hip Score (mHHS) is a joint specific score covering domains of pain, function, functional activities, absence of deformity, and hip range of motion. Scores ranged from 0 to 100, with 0 representing worse disability and 100 representing less disability.

    An increase in mHHS indicated improved hip joint function (i.e., a better outcome) and a decrease indicated worsening function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.

    Measured: Baseline to 6 months, 12 months, and 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jun 2019
  2. Study start1 Aug 2019
  3. Primary completion8 Aug 2024
  4. Study completion8 Aug 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
298 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03985839
Sponsor's protocol ID
2018.20.SMD.MRPTKT.PRO
Status last verified
Nov 2023
First submitted
11 Jun 2019
Last updated
13 Jul 2026
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Labral Tear, Glenoid and Acetabular Labrum Tear, run by Smith & Nephew, Inc. at 12 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Repair Failure Rate at 6 Months (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in